Harmony Biosciences Holdings (HRMY) - Total Assets
Based on the latest financial reports, Harmony Biosciences Holdings (HRMY) holds total assets worth $1.27 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Harmony Biosciences Holdings total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Harmony Biosciences Holdings - Total Assets Trend (2018–2025)
This chart illustrates how Harmony Biosciences Holdings's total assets have evolved over time, based on quarterly financial data. Explore HRMY long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Harmony Biosciences Holdings - Asset Composition Analysis
Current Asset Composition (December 2025)
Harmony Biosciences Holdings's total assets of $1.27 Billion consist of 71.3% current assets and 28.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.2% |
| Accounts Receivable | $96.79 Million | 7.6% |
| Inventory | $5.36 Million | 0.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $89.42 Million | 7.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Harmony Biosciences Holdings's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Harmony Biosciences Holdings market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Harmony Biosciences Holdings's current assets represent 71.3% of total assets in 2025, a decrease from 97.1% in 2018.
- Cash Position: Cash and equivalents constituted 59.2% of total assets in 2025, down from 93.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 7.6% of total assets.
Harmony Biosciences Holdings Competitors by Total Assets
Key competitors of Harmony Biosciences Holdings based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Harmony Biosciences Holdings - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.58 | 3.67 | 5.59 |
| Quick Ratio | 3.56 | 3.63 | 5.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $561.48 Million | $467.57 Million | $168.12 Million |
Harmony Biosciences Holdings - Advanced Valuation Insights
This section examines the relationship between Harmony Biosciences Holdings's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.10 |
| Latest Market Cap to Assets Ratio | 1.47 |
| Asset Growth Rate (YoY) | 27.3% |
| Total Assets | $1.27 Billion |
| Market Capitalization | $1.86 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Harmony Biosciences Holdings's assets above their book value (1.47x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Harmony Biosciences Holdings's assets grew by 27.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Harmony Biosciences Holdings (2018–2025)
The table below shows the annual total assets of Harmony Biosciences Holdings from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.27 Billion | +27.26% |
| 2024-12-31 | $999.20 Million | +23.14% |
| 2023-12-31 | $811.45 Million | +20.42% |
| 2022-12-31 | $673.87 Million | +55.47% |
| 2021-12-31 | $433.44 Million | +1.49% |
| 2020-12-31 | $427.07 Million | +300.25% |
| 2019-12-31 | $106.70 Million | +19.51% |
| 2018-12-31 | $89.28 Million | -- |
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that … Read more